abstract |
FIELD: pharmacology. n SUBSTANCE: invention relates to the pharmaceutical composition comprising an interferon-alpha conjugate with the polymer and the Raf inhibitor, and can be used in medicine. The received pharmaceutical composition is used for treating cancer with k-ras mutation. n EFFECT: invention provides a pharmaceutical composition having a prolonged in vivo half-life and greater anti-cancer activity than the interferon-alpha, thus reducing the introduced dose of the anticancer agent by reducing its side effects. n 23 cl, 6 dwg, 5 tbl, 6 ex |